Real Assets
We build future energy systems and resilient infrastructure, backing emerging opportunities in technology, land and water.
Objective:
For Gerresheimer to publish data that helps to strengthen investors’ understanding of the positive impacts enabled through its products and services.
Background:
We continually seek to further strengthen our understanding of the positive and negative impacts associated with the products and services sold by our investee companies. Additional insights allow us to build stronger investment conviction in a stock and more clearly set out the ‘impact story’. Equally, understanding negative impacts is an essential step towards addressing these impacts.
Actions:
During a call with Gerresheimer we raised the issue of product impact. Specifically, we focused on the environmental impact of their auto-injectors and pens, particularly around end-of-life disposal.
Outcomes:
M2
Gerresheimer confirmed that this issue is firmly on their agenda, and they are actively in discussions with customers to address the challenges. However, several factors make this a complex problem:
Regulatory Challenges: The pharmaceutical industry is highly regulated, and any changes to how used auto-injectors are handled must comply with strict standards. This makes it difficult to implement widespread changes quickly.
Hazardous Waste Management: Used auto-injectors are considered hazardous waste, meaning that they must be dismantled and disposed of in separate parts, which complicates the process of managing these devices responsibly.
Logistical Barriers: There are significant logistical challenges in setting up a system for returning used injectors. GXI is evaluating options for collection points, such as pharmacies or doctor's offices, but these considerations require further analysis and planning.
Gerresheimer also acknowledged that multiple-use injectors could reduce waste, although they don't completely eliminate the issue. As the market for auto-injectors is growing, the company recognises that this will become a more pressing topic in the near future and is committed to finding solutions. They are actively exploring product lifecycle improvements, but significant barriers remain that will require innovative approaches and collaboration within the industry. We will continue to raise this topic with Gerresheimer during our meetings with the company, but ultimately advancements will need to be made in collaboration with pharmaceutical companies and the FDA.
Important Information
Foresight Group LLP does not offer legal, tax, financial or investment advice and the information on this website should not be construed as such. We recommend investors seek advice from a regulated financial adviser. The opportunity described in this document may not be suitable for all investors. Any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice.
Foresight Group LLP acts as investment manager and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London SE1 9SG.
OEICs
An investment in FP Sustainable Future Themes Fund, FP Foresight Global Real Infrastructure Fund, FP Sustainable Real Estate Securities Fund, FP UK Infrastructure Income Fund or FP WHEB Sustainability Impact Fund and FP Foresight Diversified Real Assets Fund (together the “Funds”) should be considered a long-term investment that may be higher risk. Portfolio holdings are subject to change without notice.
The Authorised Corporate Directors FundRock Partners Limited (registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY) and Liontrust Investment Partners LLP (registered office 2 Savoy Court, London WC2R 0EZ), are authorised and regulated by the Financial Conduct Authority with Firm Reference Numbers 469278 and 518552 respectively. The Funds are incorporated in England and Wales.
ICAVs
An investment in the WHEB Sustainable Impact Fund and the WHEB Environmental Impact Fund (together the “Funds”) should be considered a longer-term investment that may be higher risk. Portfolio holdings are subject to change without notice.
The Manager of the Funds is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at Airport Center Building, 5, Heienhaff, L-1736 Senningerberg, Luxembourg.
We respect your privacy and are committed to protecting your personal data. If you would like to find out more about the measures, we take in processing your personal information, please refer to our privacy policy, which can be found at http://www.foresight.group/privacy-policy.